Cell death beyond apoptosis

Leukemia

Volumn 14, Issue 8, 2000, Pages 1502-1508

  Blagosklonny, M V ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Chemotherapy; Leukemia

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CASPASE 9; CASPASE INHIBITOR; CYTOCHROME C; DNA FRAGMENT; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN;

APOPTOSIS; BIOCHEMISTRY; CANCER THERAPY; CELL CULTURE; CELL DEATH; CELL GROWTH; CELL SELECTION; CELL STRUCTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 0033867955     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401864     Document Type: Review

References (123)

1. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
2. Caspases and apoptosis - biology and terminology
3. Death in embryonic systems
4. Caspase-independent programmed cell death with necrotic morphology
5. Protein or RNA synthesis inhibition induces apoptosis of mature human CD4+ T cell blasts
6. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors
7. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3
8. Constitutive expression of the machinery for programmed cell death
9. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction
10. Release of mitochondrial cytochrome C in both apoptosis and necrosis induce by beta-lapachrone in human carcinoma cells
11. Apoptosis by death factor
12. Death receptors: Signaling and modulation
13. Caspaces: Enemies within
14. Apoptotic pathways: The roads to ruin
15. Mechanisms mediating caspase activation in cell death
16. Motochondria and apoptosis
17. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE
18. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis
19. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis
20. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD
21. Involvement of caspase 3-activated DNase in internucleosomal DNA cleavage induced by diverse apoptotic stimuli
22. Extranuclear apoptosis: The role of the cytoplasm in the execution phase
23. Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity
24. Apoptosis: Cell death defined by caspase activation
25. Apoptotic death in epithelial cells: Cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation
26. Cisplatin induces apoposis in a human ovarian-carcinoma cell-line without concomitant internucleosomal degradation of DNA
27. Lack of internucleosomal DNA fragmentation is related to CI(-) efflux impairment in hematopoietic cell apoptosis
28. Internucleosomal DNA clevage triggered by plasma membrane damage during necrotic cell death. Involvement of serine but not cystein proteases
29. Mechanisms of induction of apoptotic DNA fragmentation
30. Interdigital cell death can occur through a nectrotic and caspase-independent pathway
31. Camptothecin-induced apoptosis in p53- null human leukemia HL60 cells and their isolated nuclei; effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases
32. Caspase activation without death
33. The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial premeability transition determine the mode of cell death
34. Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death
35. Apoptosis without caspases; an inefficient molecular guillotine
36. Dead or dying: Necrosis vs apoptosis in caspase-deficient human renal cell carcinoma
37. Apoptosis and drug response
38. Double identity for proteins of the Bcl-2 family
39. Expression level of Bcl-2 determines anti- or proapoptotic function
40. Conversion of Bcl-2 to a Bax-like death effector by caspases
41. Clevage of bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells
42. Mitogen-activated protein kinase pathway is dispensible for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells
43. Anti-apoptotic activity of low levels of wild-type p53
44. A matter of life and cell death
45. A node between proliferation, apoptosis, and growth arrest
46. Suppression of c-myc-induced apoptosis by Ras signalling through PI(3)K and PKB
47. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway
48. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms
49. BCR-ABL delays apoptosis upstream of procaspase-3 activation
50. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3
51. Regulation of cell death protease caspase-9 by phosphorylation
52. Senescence of human fibroblasts induced by oncogenic Raf
53. Janus faces of ras: Anti or pro-apoptotic?
54. Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: Suppression by mutant c-H-ras oncogene expression
55. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
56. Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells
57. Differential regulation of discrete apoptotic pathways by Ras
58. Induced mitotic death of HeLa cells by abnormal expression of c-H-ras
59. Proteasome-dependent regulation of p21WAF1/CIP1 expression
60. Growth factor modulation of p53-mediated growth arrest versus apoptosis
61. Differential abilities of activated Raf oncoprotiens to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells
62. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis
63. Induction of cell death by stimulation of protein kinase C in human epithelial cells expressing a mutant ras oncogene: A potential therapeutic target
64. Apoptosis of human leukemic HL-60 cells induced to differentiate by phorbol ester treatment
65. The mitogen-activated protein kinase pathway mediates growth arrest or E1A-dependent apoptosis in SKBr3 human breast cancer cells
66. Effects of phorbol esters on an interleukin-3-dependent cell line
67. Role of p53 and p21 waf1/cip1 in senescence-like terminal proliferation arrest induced in human cells by chemotherapeutic drugs
68. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer drugs
69. Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias
70. Decreased sensitivity of drug-resistant cells towards T cell cytotoxicity
71. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells
72. Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents
73. Intracellular metabolism of Ara-C and resulting DNA fragmentation and apoptosis of human AML HL-60 cells possessing disparate levels of Bcl-2 protein
74. Caspase-3-like activity is necessary but not sufficient for daunorubicin-induced apoptosis in Jurkat human lymphoblastic leukemia cells
75. Defective apoptotic signal transduction pathway downstream of caspase-3 in human B-lymphoma cells: A novel mechanism of nuclear resistance
76. Development of polyploidization in taxol resistant human leukemia cells in vitro
77. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis
78. Protease inhibitor-induced apoptosis: Accumulation wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition
79. Inhibited apoptosis and drug resistance in acute myeloid leukaemia
80. Apoptosis and resistance to daunorubicin in human leukemic cells
81. Wild-type p53 is not sufficient for serum starvation-induced apoptosis in cancer cells but accelerates apoptosis in sensitive cells
82. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics
83. Resistance to apoptosis induced by serum depletion and all-trans retinoic acid in drug-resistant leukemic cell lines
84. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: Multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and ca
85. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases)
86. Signaling defect in the activation of caspase-3 and PKCdelta in human TUR leukemia cells is associated with resistance to apoptosis
87. Distinct steps in DNA fragmentation pathway during camptothecin-induced apoptosis involved caspase-, benzyloxycarbonyl- and N-tosyl-L-phenylalanylchloromethyl ketone-sensitive activities
88. Apoptosis inducing factor (AIF): A phylogenetically old, caspase-independent effector of cell death
89. Association of high-molecular-weight DNA fragmentation with apoptotic or non-apoptotic cell-death induced by calcium ionophore
90. Cell death of AKR-2B fibroblasts after serum removal: A process between apoptosis and necrosis
91. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias
92. Drug-induced apoptosis in chronic lymphocytic leukemia
93. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human AML HL-60 cells
94. Activation of the CPP32 protease in apoptosis induced by 1-b-D arabinofuranosylcytosine and other DNA-damaging agents
95. Apoptosis in cancer therapy: Crossing the threshold
96. 7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53
97. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
98. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
99. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells
100. Decrease in susceptibility toward induction of apoptosis and alteration in G1 checkpoint function as determinants of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-hydroxystaurosporine)
101. UCN-01, a protein kinase C inhibitor, inhibits endothelial proliferation and angiogenic hypoxic response
102. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis
103. Activation of the cell death program by inhibition of proteasome function
104. The role of the ubiquitin-proteasome pathway in apoptosis
105. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes
106. Proteasome inhibitors: A novel class of potent and effective antitumor agents
107. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
108. Apoptosis in leukocytes
109. Epithelial apoptosis
110. Dysregulation of apoptosis in cancer
111. Apoptosis and therapy
112. P53, cell cycle control and apoptosis: Implications for cancer
113. Apoptosis in antitumor strategies-modulation of cell-cycle or differentiation
114. Apoptosis in human disease: A new skin for the old ceremony
115. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses
116. Apoptosis and the dilemma of cancer chemotherapy
117. Apoptosis as a goal of cancer therapy
118. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
119. Selective killing of transformed baby hamster kidney (BHK) cells
120. A restriction point for control of normal animal cell proliferation
121. A chemical inhibitor of p53 that protects mice from the side-effects of cancer therapy
122. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs
123. Drug-resistance enables selective killing of resistant leukemia cells: Exploiting of drug resistance instead of reversal